Biogen Idec Inc.
46Patents
15Active
46Granted
42Portfolio score
Filing activity: Jan 28, 1999 → Jul 16, 2015 · 12 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7422739B2 | Anti-CD20 antibodies | Emerging Cross-Sectional Technologies | 138 | Expired |
| US7820161B1 | Treatment of autoimmune diseases | Emerging Cross-Sectional Technologies | 121 | Expired |
| US6896885B2 | Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma | Human Necessities | 88 | Expired |
| US6897044B1 | Production of tetravalent antibodies | Chemistry; Metallurgy | 82 | Expired |
| US7682612B1 | Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody | Human Necessities | 78 | Expired |
| US8329172B2 | Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody | Chemistry; Metallurgy | 58 | Active |
| US8557244B1 | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody | Emerging Cross-Sectional Technologies | 53 | Expired |
| US8545843B2 | Treatment of vasculitis | Emerging Cross-Sectional Technologies | 49 | Active |
| US7220356B2 | Method of purifying polypeptides by simulated moving bed chromatography | Physics | 47 | Expired |
| US7759117B2 | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures | Emerging Cross-Sectional Technologies | 23 | Active |
| US7381560B2 | Expression and use of anti-CD20 antibodies | Emerging Cross-Sectional Technologies | 22 | Expired |
| US6733763B2 | Induction of cytotoxic T-lymphocyte responses | Emerging Cross-Sectional Technologies | 21 | Expired |
| US7319139B2 | TAG-72 specific CH2 domain deleted antibodies | Chemistry; Metallurgy | 21 | Expired |
| US7235360B2 | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same | Chemistry; Metallurgy | 20 | Expired |
| US8206711B2 | Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies | Human Necessities | 19 | Active |
| US7744877B2 | Expression and use of anti-CD20 Antibodies | Emerging Cross-Sectional Technologies | 18 | Active |
| US6998125B2 | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis | Emerging Cross-Sectional Technologies | 16 | Expired |
| US7122187B2 | Treating autoimmune diseases with humanized anti-CD40L antibody | Physics | 15 | Expired |
| US7157276B2 | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures | Emerging Cross-Sectional Technologies | 12 | Expired |
| US7294753B2 | Method for preparing anti-MIF antibodies | Human Necessities | 12 | Expired |
| US7338658B2 | Recombinant anti-CD4 antibodies for human therapy | Chemistry; Metallurgy | 12 | Expired |
| US6955810B2 | Method for the treatment of inflammatory disorders | Chemistry; Metallurgy | 11 | Expired |
| US7074406B2 | Treating allergic diseases with humanized anti-CD40L antibody | Physics | 11 | Expired |
| US8608960B2 | Method of purifying polypeptides by simulated moving bed chromatography | Physics | 8 | Active |
| US7192585B2 | CD80 specific antibodies | Chemistry; Metallurgy | 8 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.